Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald maintains a Hold rating on Quest Diagnostics (DGX) and raises the price target from $145 to $150.
April 24, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Hold rating on Quest Diagnostics and raises the price target from $145 to $150.
The increase in the price target by Truist Securities suggests a positive outlook on the stock's value, potentially leading to increased investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100